These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31446247)

  • 1. 1,2,4-Oxadiazole derivatives targeting EGFR and c-Met degradation in TKI resistant NSCLC.
    Dokla EME; Fang CS; Abouzid KAM; Chen CS
    Eur J Med Chem; 2019 Nov; 182():111607. PubMed ID: 31446247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
    El-Sayed NA; Nour MS; Salem MA; Arafa RK
    Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker.
    Xu C; Han Y; Xu S; Wang R; Yue M; Tian Y; Li X; Zhao Y; Gong P
    Eur J Med Chem; 2020 Jan; 186():111867. PubMed ID: 31757525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C; Xu S; Peng L; Zhang B; Zhang H; Hu Y; Zheng P; Zhu W
    J Enzyme Inhib Med Chem; 2019 Dec; 34(1):203-217. PubMed ID: 30835140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R/T790M/C797S mutant EGFR tyrosine kinase inhibitors.
    Lei H; Fan S; Zhang H; Liu YJ; Hei YY; Zhang JJ; Zheng AQ; Xin M; Zhang SQ
    Eur J Med Chem; 2020 Jan; 186():111888. PubMed ID: 31787359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational design-aided discovery of novel 1,2,4-oxadiazole derivatives as potential EGFR inhibitors.
    Unadkat V; Rohit S; Parikh P; Sanna V; Singh S
    Bioorg Chem; 2021 Sep; 114():105124. PubMed ID: 34328857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
    Fathi MAA; Abd El-Hafeez AA; Abdelhamid D; Abbas SH; Montano MM; Abdel-Aziz M
    Bioorg Chem; 2019 Mar; 84():150-163. PubMed ID: 30502626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
    Yamaoka T; Ohba M; Arata S; Ohmori T
    J Vis Exp; 2017 Aug; (126):. PubMed ID: 28829429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis, and antiproliferative activity of new indole/1,2,4-triazole/chalcone hybrids as EGFR and/or c-MET inhibitors.
    Mahmoud E; Abdelhamid D; Youssif BGM; Gomaa HAM; Hayallah AM; Abdel-Aziz M
    Arch Pharm (Weinheim); 2024 Sep; 357(9):e2300562. PubMed ID: 39219313
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of 4,6-pyrimidinediamine derivatives as novel dual EGFR/FGFR inhibitors aimed EGFR/FGFR1-positive NSCLC.
    Xie Z; Wu K; Wang Y; Pan Y; Chen B; Cheng D; Pan S; Guo T; Du X; Fang L; Wang X; Ye F
    Eur J Med Chem; 2020 Feb; 187():111943. PubMed ID: 31846829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Treatment with Triptolide and Tyrosine Kinase Inhibitors Synergistically Enhances Apoptosis in Non-small Cell Lung Cancer H1975 Cells but Not H1299 Cells through EGFR/Akt Pathway.
    Tong X; Jiang P; Li Y; Guo L; Zhang HM; Zhang BK; Yan M
    Chem Pharm Bull (Tokyo); 2019 Aug; 67(8):864-871. PubMed ID: 31142691
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
    Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
    Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW; Chen TC; Huang HS; Lee H
    Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of 2(1H)-pyrimidinones as potential EGFR T790M inhibitors for the treatment of gefitinib-resistant non-small cell lung cancer.
    Huang J; Huang J; Wang N; Wang L; Li L; Wang C; Sun X; Li Y; Huang G; Ma X
    Bioorg Chem; 2019 Aug; 89():102994. PubMed ID: 31185393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and evaluation of antitumor activity of Mobocertinib derivatives, a third-generation EGFR inhibitor.
    Fan D; Zhang H; Duan L; Long L; Xu S; Tu Y; Wang L; Zheng P; Zhu W
    Bioorg Chem; 2024 Jun; 147():107390. PubMed ID: 38691904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and antitumor evaluation of novel 4-anilino-7,8-dihydropyrido[4,3-d]pyrimidine-6(5H)-carboxylate derivatives as potential EGFR inhibitors.
    Zhang D; Yan Y; Jin G; Liu B; Ma X; Han D; Jia X
    Arch Pharm (Weinheim); 2018 Sep; 351(9):e1800110. PubMed ID: 30048007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and bioevaluation and doking study of 1H-pyrrolo[2,3-b]pyridine derivatives bearing aromatic hydrazone moiety as c-Met inhibitors.
    Wang W; Xu S; Duan Y; Liu X; Li X; Wang C; Zhao B; Zheng P; Zhu W
    Eur J Med Chem; 2018 Feb; 145():315-327. PubMed ID: 29331754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of novel EGFR-PROTACs capable of degradation of multiple EGFR-mutated proteins.
    Du Y; Shi S; Shu C; He Y; Xu W; Wu D; Tian Y; Kong M; He J; Xie W; Qiu Y; Xu Y; Zou Y; Zhu Q
    Eur J Med Chem; 2024 Jun; 272():116489. PubMed ID: 38759458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities.
    Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH
    Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.